一种新型大环内酯类药物A-56268与罗红霉素、红霉素及克林霉素的体外活性比较
In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.
作者信息
Barry A L, Thornsberry C, Jones R N
出版信息
Antimicrob Agents Chemother. 1987 Feb;31(2):343-5. doi: 10.1128/AAC.31.2.343.
Abstract
A new macrolide (A-56268) was found to be approximately twice as active as erythromycin and four to eight times more active than roxithromycin. All three macrolides were similar in their potency against anaerobes. Human plasma enhanced the antistaphylococcal activity of A-56268 and erythromycin but reduced the activities of roxithromycin and clindamycin.
摘要
一种新的大环内酯类药物（A - 56268）的活性约为红霉素的两倍，比罗红霉素高4至8倍。这三种大环内酯类药物对厌氧菌的效力相似。人血浆增强了A - 56268和红霉素的抗葡萄球菌活性，但降低了罗红霉素和克林霉素的活性。
相似文献
1
In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.
Antimicrob Agents Chemother. 1987 Feb;31(2):343-5. doi: 10.1128/AAC.31.2.343.
2
In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.
Antimicrob Agents Chemother. 1988 May;32(5):752-4. doi: 10.1128/AAC.32.5.752.
3
Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Antimicrob Agents Chemother. 1999 Aug;43(8):2027-31. doi: 10.1128/AAC.43.8.2027.
4
Comparative in vitro activity of the new macrolide A-56268 against anaerobic bacteria.
Eur J Clin Microbiol. 1987 Aug;6(4):492-4. doi: 10.1007/BF02013121.
5
[In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes].
Pathol Biol (Paris). 1986 May;34(5):440-4.
6
Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
Eur J Clin Microbiol Infect Dis. 1990 Jan;9(1):30-3. doi: 10.1007/BF01969529.
7
Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
Antimicrob Agents Chemother. 1997 Sep;41(9):1867-70. doi: 10.1128/AAC.41.9.1867.
8
Josamycin and rosamicin: in vitro comparisons with erythromycin and clindamycin.
Antimicrob Agents Chemother. 1976 Oct;10(4):773-5. doi: 10.1128/AAC.10.4.773.
9
In-vitro comparison of roxithromycin and erythromycin against 900 anaerobic bacterial strains.
J Antimicrob Chemother. 1987 Nov;20 Suppl B:13-9. doi: 10.1093/jac/20.suppl_b.13.
10
In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.
Clin Microbiol Infect. 2001 Jul;7(7):362-6. doi: 10.1046/j.1198-743x.2001.00280.x.
引用本文的文献
1
Advances in the Prevention of Infection-Related Preterm Birth.
Front Immunol. 2015 Nov 16;6:566. doi: 10.3389/fimmu.2015.00566. eCollection 2015.
2
Tacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitis.
PLoS One. 2014 Dec 2;9(12):e114386. doi: 10.1371/journal.pone.0114386. eCollection 2014.
3
Design and formulation technique of a novel drug delivery system for azithromycin and its anti-bacterial activity against Staphylococcus aureus.
AAPS PharmSciTech. 2013 Sep;14(3):1045-54. doi: 10.1208/s12249-013-9993-6. Epub 2013 Jun 26.
4
Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis.
Am J Obstet Gynecol. 2011 Sep;205(3):177-90. doi: 10.1016/j.ajog.2011.03.047. Epub 2011 Apr 2.
5
Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.
Drugs. 1996 Mar;51(3):483-505. doi: 10.2165/00003495-199651030-00013.
6
Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role.
Agents Actions. 1993 Jan;38(1-2):85-90. doi: 10.1007/BF02027218.
7
Clarithromycin clinical pharmacokinetics.
Clin Pharmacokinet. 1993 Sep;25(3):189-204. doi: 10.2165/00003088-199325030-00003.
8
Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1994 Aug;48(2):297-326. doi: 10.2165/00003495-199448020-00011.
9
World-wide development of antibiotic resistance in pneumococci.
Eur J Clin Microbiol. 1987 Aug;6(4):367-77. doi: 10.1007/BF02013089.
10
Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test.
J Clin Microbiol. 1988 Nov;26(11):2415-20. doi: 10.1128/jcm.26.11.2415-2420.1988.
本文引用的文献
1
Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin.
Antimicrob Agents Chemother. 1981 Feb;19(2):335-6. doi: 10.1128/AAC.19.2.335.
2
In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 1984 Apr;25(4):529-31. doi: 10.1128/AAC.25.4.529.
3
In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.
Antimicrob Agents Chemother. 1983 Aug;24(2):209-15. doi: 10.1128/AAC.24.2.209.
4
Effect of several components of anaerobic incubation on antibiotic susceptibility test results.
Antimicrob Agents Chemother. 1972 May;1(5):433-40. doi: 10.1128/AAC.1.5.433.
5
Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).
Mayo Clin Proc. 1985 Mar;60(3):189-203. doi: 10.1016/s0025-6196(12)60219-5.
6
In vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of Haemophilus influenzae.
Antimicrob Agents Chemother. 1986 May;29(5):921-2. doi: 10.1128/AAC.29.5.921.
7
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.
Antimicrob Agents Chemother. 1986 Dec;30(6):865-73. doi: 10.1128/AAC.30.6.865.
8
Aerobically incubated thioglycolate broth disk method for antibiotic susceptibility testing of anaerobes.
Antimicrob Agents Chemother. 1976 Oct;10(4):727-32. doi: 10.1128/AAC.10.4.727.
9
In vitro activity of rosamicin, josamycin, erythromycin, and clindamycin against beta-lactamase-nagative and beta-lactamase-positive strains of Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 1979 Feb;15(2):243-5. doi: 10.1128/AAC.15.2.243.
Zotero 插件